Pharmaceutical companies invest significant time and money in drug development, making FDA rejections costly and detrimental for both finances and patient care.
Regulatory rejections can stem from various reasons, with poor software quality emerging as a crucial but often overlooked factor in recent years.
Software quality encompasses applications, programming environments, languages, and data processing tools, with regulatory bodies increasingly scrutinizing compliance in this realm.
GxP compliance is essential for smooth transitions to new technologies like open-source tools; understanding cases of software quality issues leading to FDA rejections is key to prevention.
Common reasons for FDA rejections include insufficient clinical evidence, manufacturing and quality concerns, incomplete applications, and safety issues, all of which can be impacted by software quality.
The FDA closely examines software tools and methodologies used in data analysis, clinical trials, and regulatory submissions, emphasizing the importance of compliance in software development.
Poor software quality can result in devastating FDA rejections, as evidenced by cases like Applied Therapeutics losing three-quarters of its valuation due to clinical application deficiencies.
FDA inspections, including pre-approval, routine GMP, for-cause, follow-up, BIMO, post-market, and foreign inspections, are conducted to verify compliance and assess manufacturing processes.
Publicly available FDA inspection reports highlight software-related compliance issues such as software bugs, security flaws, inadequate validation processes, lack of access controls, and missing documentation.
Appsilon helps companies achieve GxP compliance by offering services such as compliance audits, building compliant Shiny dashboards in R and Python, and guiding through FDA and EMA submissions.